Positrigo on a growth momentum in the US

Positrigo’s NeuroLF system is an FDA-cleared ultra-compact brain Positron Emission Tomography (PET) scanner, a nuclear medical imaging device to advance functional brain imaging. As the first device of its kind to gain market clearance in the US and EU, the device is used in the assessment of causes of dementias such as Alzheimer’s disease and other brain related disorders.

Presently, the availability of disease-modifying therapies for Alzheimer’s disease in the US has created an increased demand for brain PET scans. Leveraging this market opportunity, Positrigo has established a strong presence in the US as its key market, where several devices have already been sold. Most recently, Beverly Hills Medical Imaging (BHMI) acquired NeuroLF, becoming the first outpatient imaging center in California to adopt the technology. Installation is scheduled for December this year. Furthermore, the company announced the The Neuron Clinic in San Marcos, California, has become the first neurology practice in the United States to purchase and use the NeuroLF system for point-of-care brain PET imaging.

While Positrigo envisions the US as its key market, the company maintains sales in the European Union. The first devices have been sold in Germany and Italy, with planned installations later this year. Pursuant to its European expansion strategy, the startup has appointed two new distributors, APR Salud in Spain and Qualimedis in France, to drive commercial expansion in Europe.

Besides accelerating market growth, Positrigo has strengthened its board with the appointment of three experienced new board members this year. The management team has been expanded with the addition of Jerome Descheirder as Global Chief Commercial Officer, Matthieu Cousteau as Chief Financial Officer and Brian Oswald as VP of US Sales.

The current advancements are funded through equity investments, including a new round underway. Kineo Finance is one of the participating venture capital firms.

(RAN)